Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 8:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–160 of 160 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: sofosbuvir Clear all

Conditions: Hepatitis C, Chronic, Pregnancy; Infection
Interventions: Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet; Drug
Lead sponsor: Catherine Anne Chappell; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 6
States / cities: Cincinnati, Ohio • Columbus, Ohio • Pittsburgh, Pennsylvania + 3 more

Conditions: Heart Failure
Interventions: Zepatier; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hematopoietic Stem Cell Transplantation
Interventions: Ledipasvir 90mg/Sofosubvir 400mg; Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Duarte, California • Los Angeles, California

Conditions: Hepatitis C, Cryoglobulinemia
Interventions: Harvoni, Epclusa; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C, Opioid-Related Disorders, Injection Drug Use
Interventions: Sofosbuvir/velpatasvir (Epclusa®); Drug
Lead sponsor: Jennifer Havens; Other
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Hazard, Kentucky

Conditions: Hepatitis C Virus Infection
Interventions: Sofosbuvir, Ribavirin, LDV/SOF, SOF/VEL, SOF/VEL/VOX, Other SOF-Based Regimen, Ineligible parent treatment; Drug · Other
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 1,609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 77
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 57 more

Conditions: Renal Failure Chronic, Hepatitis C
Interventions: Zepatier, Zepatier plus Sofosbuvir; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV-1 Infection, Hepatitis
Interventions: Sofosbuvir, Ribavirin, Ledipasvir/Sofosbuvir; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 12
States / cities: San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 7 more

Conditions: HCV Infection
Interventions: SOF, RBV, LDV/SOF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 7
States / cities: San Francisco, California • Miami, Florida • Chicago, Illinois + 4 more

Conditions: Hepatitis C
Interventions: SOF, VEL, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 40
States / cities: Long Beach, California • Los Angeles, California • Pasadena, California + 37 more

Conditions: Hepatitis C
Interventions: LDV/SOF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatitis C and HIV Coinfection
Interventions: Blood draws for tenofovir PK, renal function; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL/VOX, SOF/VEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 43
States / cities: Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more

Conditions: Hepatitis C Infection, HIV Infection
Interventions: Sofosbuvir, Ribavirin, and Stribild; Drug
Lead sponsor: Saint Michael's Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Lung Diseases
Interventions: Zepatier, Epclusa; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 67 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hepatitis C
Interventions: DCV/ASV/BMS-791325, Ribavirin, Sofosbuvir, Peginterferon α-2a; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: Rialto, California • Chicago, Illinois • Indianapolis, Indiana + 2 more

Search by objective public record fields.

Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy

Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV)

Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients.

Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia

The Kentucky Viral Hepatitis Treatment Study

A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection

Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant

Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection

Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency

Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection

Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection

Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir

Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor

Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study

Transplanting Hepatitis C Lungs Into Negative Lung Recipients

Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)